Northwest Biotherapeutics Announces Effectiveness of Reverse Stock Split

BOTHELL, Washington, June 28 /PRNewswire/ --

Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT) today
announced that it has been advised by NASDAQ that, starting today, June 28,
2008, its shares of common stock will trade under the symbol NWBO with a
CUSIP number 6637P501 and will reflect the effect of the one-for fifteen
reverse stock split which was previously announced and took effect on June
19, 2007.

As a result of the reverse stock split, every 15 shares of Northwest
Biotherapeutics' common stock were combined into one common share. No scrip
or fractional certificates will be issued in connection with the reverse
stock split. Stockholders who would be entitled to fractional shares will
receive cash in lieu of receiving fractional shares. The reverse stock split
resulted in similar adjustments to Northwest Biotherapeutics' outstanding
common stock options and warrants and shares of common stock reserved for
issuance pursuant to its current equity plans.

Registered stockholders of Northwest Biotherapeutics who hold existing
physical stock certificates will receive a letter of transmittal from
Northwest Biotherapeutics' transfer agent, Mellon Investor Services,
containing instructions on how to receive new share certificates.
Stockholders whose certificates are held in "street name," or on deposit with
their brokerage firms, will need to take no further action.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products that treat cancers more effectively than
current treatments, without toxicity, on a cost-effective basis. The Company
has two broad platform technologies: dendritic cell-based vaccines, and
therapeutic antibodies. The Company's three lead product candidates are:

-- DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of
       Glioblastoma multiforme, which has entered into a large Phase II
       pivotal clinical trial cleared by the FDA;
    -- DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment
       of hormone independent non-metastatic prostate cancer, which is ready
       to enter a Phase III pivotal clinical trial cleared by the FDA; and
    -- Monoclonal antibodies to CXCR4, which are in late pre-clinical
       development for the treatment of multiple cancers.



For further information, please visit the company web site at
http://www.nwbio.com.

Statements made in this news release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "expects," "believes,"
"intends," and similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those projected in any
forward-looking statement. Additional information on factors, which could
affect the company's results, is included in its Securities and Exchange
Commission ("SEC") filings. Finally, there may be other factors not mentioned
above or included in the company's SEC filings that may cause actual results
to differ materially those projected in any forward-looking statement. You
should not place undue reliance on any forward-looking statements. The
company assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as required
by securities laws.

Web site: http://www.nwbio.com